Skip to main content
SpringerLink
Log in

Biological or targeted synthetic DMARDs increase COVID-19 severity

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sparks J, et al. ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE Annals of the Rheumatic Diseases 80 (Suppl. 1): 19 May 2021. Available from: URL: http://dx.doi.org/10.1136/annrheumdis-2021-eular.1632

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biological or targeted synthetic DMARDs increase COVID-19 severity. Reactions Weekly 1860, 10 (2021). https://doi.org/10.1007/s40278-021-97465-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-97465-3

Search

Navigation